Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The price of this stock will increase substantially in a very short time once we receive news. The last press release on 2 million dollar funding The proceeds will be used for development of the Company’s recently announced Coronavirus treatment on a priority basis and the clinical development of Adva-27a, the Company’s flagship anticancer compound targeted for pancreatic cancer.
Clinical trials for Pancreatic Cancer indication are planned to
be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.
Pancreatic cancer is a killer that cares not about how old you are, what your name is or your status in life. Alex Trebek, the host of Jeopardy worth 75 million dollars is in stage 4 pancreatic cancer and they didn't discover he had it until the latter stages. A cure just for pancreatic cancer would send a stock to orbit.
I've had friends that have died from pancreatic cancer, which was a terrible ordeal they went through. These trials will take time. I will just standby and patiently wait
SBFM has made many advancements since 2011. Patience to all and only the best for each of us.
Articles
August 4, 2011
Sunshine Biopharma Looking to Mimic Roche’s Billion-Dollar Cancer Drug August 4, 2011
Last year, over 260,000 new cases of breast cancer (invasive and in situ combined) were diagnosed in women in the...
Lest we never forget, we've grown stronger from a terrible 9-11 in the past. I am hoping this insignificant happening on 9-11 will only make each of us that are holding and not selling SBFM stronger, wiser and wealthier.
Patience is the companion of wisdom.
I wish only the best for each of us and may we take time to remember that first 9-11 and the sacrifices that were made and I pray that it will never happen again.
TRT and SBFM old info
https://www.companiesofcanada.com/company/414676-0/trt-pharma-inc
Patents Posted for May 22, 2020. Didn't have time to check to see if SBFM was posted.
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=0&f=S&l=50&d=PG01&p=7&S1=20200522.AD.&Page=Next&OS=APD/20200522&RS=APD/20200522
Like the little calf said to its mother, I'm here to the udder end. Patience, Patience, Patience. Rome wasn't built in a day.
I am determined to stay with this stock. I have had many relatives and friends that have battled cancer, and many have died of cancer. No family is exempt and no age is exempt. Lets work toward destroying this enemy along with destroying all coronavirus. For me this is not just about money but hopefully destroying two monsters. Only the best for each of us.
I would also like to thank you Col317 and mrpennystocks for all the great info. Others also have been a great help on this board. I have done my dd
and also followed up on your posts and I can only conclude this company is legit and a good investment. I wish only the best to each of us.
I stand corrected. I misunderstood the post. The R/M post was for SBFM.
Correction, According to post# 64239 my understanding is the reverse merger was for THC.
that ticker was $THC which had a reverse merger yesterday. info is still there under that ticker.
According to post# 64205 my understanding is the reverse merger was for THC.
that ticker was $THC which had a reverse merger yesterday. info is still there under that ticker.
Sunshine Biopharma, Inc. (OTCMKTS:SBFM) Heats Up Fast
BY BOE RIMES ON JUNE 3, 2020
Post Views: 1,625
Sunshine Biopharma, Inc. (OTCMKTS:SBFM) is making a big move up after the Company anounced it has filed a patent application for a new coronavirus COVID-19 Treatment. The stock was trading in double zero land before the news and has been rocketing up since.
According to Sunshine Biopharma its patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease (Mpro), an enzyme that is essential for viral replication. The small molecules covered by the patent application were computer modelled and designed by Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. The patent application has a priority date of May 22, 2020.
Sunshine Biopharma, Inc. (OTCMKTS:SBFM) bills itself as a pharmaceutical company operating in the pharmaceutical testing services sector, as well as, in the research, development and commercialization of drugs for the treatment of cancer. Sunshine Biopharma’s business plan includes the clinical development of Adva-27a, the Company’s proprietary anticancer compound. Tests conducted on Adva-27a have demonstrated the drug’s effectiveness at destroying Multidrug Resistant Cancer Cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada.
Sunshine Biopharma conducts its operations through three (3) wholly owned subsidiaries: Atlas Pharma Inc. (“Atlas”), a Canadian company dedicated to chemical analysis of pharmaceutical and other industrial samples. Atlas’ operations are authorized by a Drug Establishment License issued by Health Canada. Atlas is also registered with the FDA.
Sunshine Biopharma Canada Inc. (“Sunshine Canada”), a Canadian company formed in 2014 for the purposes of offering generic prescription pharmaceuticals in Canada and elsewhere around the world. Sunshine Canada has signed licensing agreements for four (4) generic prescription drugs for the treatment of breast cancer, prostate cancer and BPH (Benign Prostatic Hyperplasia).
NOX Pharmaceuticals, Inc. (“NOX”) is a Colorado corporation dedicated to the research, development and commercialization of proprietary drugs including Adva27a, the Company’s flagship proprietary drug for the treatment of cancer. Adva-27a, is a small molecule that has proven effective against different types of multidrug resistant cancer including breast cancer cells (MCF-7/MDR), small-cell lung cancer cells (H69AR), uterine carcinoma cells (MES-SA/Dx5) and pancreatic cancer cells (Panc-1).
Microcap Daily
Sunshine Biopharma, Inc. (OTCMKTS:SBFM) Heats Up Fast
BY BOE RIMES ON JUNE 3, 2020
Post Views: 1,625
Sunshine Biopharma, Inc. (OTCMKTS:SBFM) is making a big move up after the Company anounced it has filed a patent application for a new coronavirus COVID-19 Treatment. The stock was trading in double zero land before the news and has been rocketing up since.
According to Sunshine Biopharma its patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease (Mpro), an enzyme that is essential for viral replication. The small molecules covered by the patent application were computer modelled and designed by Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. The patent application has a priority date of May 22, 2020.
Sunshine Biopharma, Inc. (OTCMKTS:SBFM) bills itself as a pharmaceutical company operating in the pharmaceutical testing services sector, as well as, in the research, development and commercialization of drugs for the treatment of cancer. Sunshine Biopharma’s business plan includes the clinical development of Adva-27a, the Company’s proprietary anticancer compound. Tests conducted on Adva-27a have demonstrated the drug’s effectiveness at destroying Multidrug Resistant Cancer Cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada.
Sunshine Biopharma conducts its operations through three (3) wholly owned subsidiaries: Atlas Pharma Inc. (“Atlas”), a Canadian company dedicated to chemical analysis of pharmaceutical and other industrial samples. Atlas’ operations are authorized by a Drug Establishment License issued by Health Canada. Atlas is also registered with the FDA.
Sunshine Biopharma Canada Inc. (“Sunshine Canada”), a Canadian company formed in 2014 for the purposes of offering generic prescription pharmaceuticals in Canada and elsewhere around the world. Sunshine Canada has signed licensing agreements for four (4) generic prescription drugs for the treatment of breast cancer, prostate cancer and BPH (Benign Prostatic Hyperplasia).
NOX Pharmaceuticals, Inc. (“NOX”) is a Colorado corporation dedicated to the research, development and commercialization of proprietary drugs including Adva27a, the Company’s flagship proprietary drug for the treatment of cancer. Adva-27a, is a small molecule that has proven effective against different types of multidrug resistant cancer including breast cancer cells (MCF-7/MDR), small-cell lung cancer cells (H69AR), uterine carcinoma cells (MES-SA/Dx5) and pancreatic cancer cells (Panc-1).
Microcap Daily
Greetings to each of you and the best to ALL of us.
News Releases
04/10/2019
Lexington Biosciences Converts Amounts Owed to Unsecured Demand Loans is now posted on https://thecse.com/en/listings/life-sciences/lexington-biosciences-inc
Look under News.
Lexington Biosciences, Inc.
Suite 1900, 1055 West Hastings Street
Vancouver, British Columbia, Canada V6E 2E9
Lexington Biosciences Converts Amounts Owed to Unsecured Demand Loans
VANCOUVER, BRITISH COLUMBIA – October 3, 2019 - Lexington Biosciences, Inc. (CSE: LNB) (the “Company” or “Lexington”) announces that it has reached agreement with third parties as well as certain directors and officers (collectively the “lenders”) of the Company to convert previous advances and unpaid amounts for services received of $654,186, in aggregate, into unsecured demand loans bearing interest at 16% per annum. As a result of the interest being applied retroactively to the date the advances or services were made the Company owed these parties $744,203 as at September 30, 2019, which is the aggregate amount of the unsecured demand loans issued.
In consideration for the conversion of the advances into unsecured demand loans, the Company will issue a total of 14,880,465 bonus warrants (“Warrants”) to the lenders at a deemed price per share of $0.05. The Warrants will be exercisable for a period of 24 months into common shares of the Company at a price of $0.05 each.
On Behalf of the Board,
“Eric Willis”
Eric Willis
CEO & Director
CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Cautionary Note Regarding Forward-Looking Statements
This news release contains forward-looking statements relating to the potential sale of the HeartSentry technology and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include those relating to the ability to complete the sale and other risks detailed from time to time in the filings made by the Company with securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward- looking statements as expressly required by applicable law.
CONTACT:
Lexington Biosciences, Inc.
+1 (800) 320-2640
info@lexingtonbiosciences.com
www.lexingtonbiosciences.com
Greetings to each of you and the best to ALL of us.
Monthly progress report for the months ended June 2019 and July 2019. Posted on https://thecse.com/en/listings/life-sciences/lexington-biosciences-inc
Look under CSE Filings.
Greetings to each of you and the best to ALL of us.
Monthly progress report for the month ended April 2019 is now posted on https://thecse.com/en/listings/life-sciences/lexington-biosciences-inc
Look under CSE Filings.
Greetings to each of you and the best to ALL of us.
I'm still in and have a great sum of shares and not going anywhere until all is done. If this unit can do everything they say it can, I would love to see it marketed for my children and grandchildren's sake. Like many families across the country and world, my family could have been spared many heartaches with this medical device called Heart Sentry. Maybe in a few more days when the China and U.S. trade agreement is signed, more avenues will be opened for Heart Sentry. I wish ONLY THE BEST FOR ALL OF US.
Greetings to each of you and the best to ALL of us.
Monthly progress report for the month ended March 2019 posted on https://thecse.com/en/listings/life-sciences/lexington-biosciences-inc
Look under CSE Filings.
Greetings to each of you and the best to ALL of us.
Notice who showed up buying on https://thecse.com/en/listings/life-sciences/lexington-biosciences-inc
Virtu ITG Canada Corp
Greetings to each of you and the best to ALL of us.
Monthly progress report for the month ended February 28, 2019 posted on https://thecse.com/en/listings/life-sciences/lexington-biosciences-inc
Look under CSE Filings.
Greetings to each of you and the best to ALL of us.
The following is an excerpt of news posted on Lexington website concerning amount needed and who can and cannot participate.
https://lexingtonbiosciences.com/news/lexington-announces-non-brokered-private-placement/
Lexington Announces Non-Brokered Private Placement
August 27, 2018
The Company now intends to sell, by way of a non-brokered private placement up to 5 million units of the Company (“Units”) at a price of $0.15 per Unit for gross proceeds of up to $750,000 (the “Offering”).
This press release does not constitute an offer to sell or solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
Greetings to each of you and the best to ALL of us.
I am holding fast and added more today.
Greetings to each of you and the best to ALL of us.
Monthly progress report for the month ended January 31, 2019 posted on https://thecse.com/en/listings/life-sciences/lexington-biosciences-inc
Look under CSE Filings. Nothing new since Dec. 2018 report.
Greetings to each of you and the best to ALL of us.
I would also like to thank Gopherdat and Sabre and others for sharing information that has been a tremendous help for me and others.
In 2011 I had open heart surgery. They removed my aortic root and replaced it with dacron, removed my aortic valve and replaced it with a mechanical valve and installed a pacemaker. I will be on coumadin, (rat poison) for the rest of my life but, I must keep my INR in check.
I am a true believer in the potential Heart Sentry has to offer all the ones that have never had a heart problem and all the ones that are having heart problems. Again, I thank each of you for your help on this board.
I wish each of you a Merry Christmas and a happy and prosperous new year.
Lexington Biosciences (QB)
Ticker Symbol: USOTC:LXGTF
OTC Market Tier: OTCQB
CIK Number:
Security Type: Ordinary Shares
LXGTF Address: Suite 1900, 1055 West Hastings Street
Vancouver, British Columbia V6E 2E9
LXGTF Country: Canada
LXGTF Phone: 1 800 320 2640
LXGTF Fax #: N/A
Website: https://www.lexingtonbiosciences.com
Description: Lexington Biosciences is a medical device company that is developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person's vascular endothelium, the vital innermost lining of a person's cardiovascular system. Traditionally, this has only been measured using ultrasound and other complex, difficult to use technologies. The HeartSentry technology core research was created at the University of California Berkeley over a fifteen-year period involving many studies and product iterations resulting in a portfolio of multiple pending and issued patents licensed to the company. The company is in the final stages of releasing the developed product for clinical studies. The aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person's cardiovascular health. Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry.
SIC Code / Description: 3841 / Surgical and medical instruments
Shares Authorized:
Shares Outstanding: 37,978,401
Shares Outstanding Date: 10/09/2018
Shares Holder Count: N/A
Shares Holder Date: N/A
Market Capitalization: $ 3,452,236.65
Key Executives: Doug Janzen - Chairman
Eric Willis - President
John Bryan Disher - Dir.
Nick Furber - CFO
Victoria Bantz - Legal Counsel
Number of Employees: N/A
Incorporation State: BC
Incorporation Country: Canada
Incorporation Year: 2016
Auditor: Crowe MacKay LLP
Auditor Address: 1100 - 1177 West Hastings Street
Vancouver, BC V6E 4T5
Canada
Auditor Website: N/A
IR Firm: Ian Murray
IR Firm Address: N/A
IR Firm Website: N/A
Legal Counsel: DuMoulin Black LLP
Legal Counsel Address: Suite 1000
Suite 1000
Vancouver, BC V6C 2T5
CAN
Legal Counsel Website: http://www.dumoulinblack.com
Fiscal Year End: 12/31
Reporting Status: International Reporting
Bankrupt: No
Shell: No
Audit Status: Yes
ADR Ratio: N/A
Transfer Agent: AST Trust Company Canada
TA Address: 1066 West Hastings Street
Vancouver, BC V6E 3X1
Canada
Depository Website: N/A
SHO Flag: N/A
3210 Flag: N/A
Short Volume: 4,608
Short Date: 09/14/2018
Closing MMID: 8
BFCMmid: 5
Tier ID: 10
Status: Active
Greetings to each of you and the best to ALL of us.
https://techstockinsider.com/the-wearable-tech-thats-disrupting-an-industry-worth-billions/
4th and Goal movie was directed by Nina Gilden Seavey.
DVD Release Date: September 20, 2011.
Actors: George Rush, Randy Sims, Albert Toeaina, Gibril Wilson, DeQawn Mobley
You can watch 4th and Goal on Amazon Prime or buy the dvd on Amazon.